Duplication or deletion of 16p11.2 — a much-studied chromosomal region with a strong association with autism — is present in 0.76 percent of people with the disorder, according to a meta-analysis published February in Genetics in Medicine.

A genetic database of autism genes, called Autism Database, or AutDB, details curated information for more than 200 mouse models of autism, according to a report in the January BMC Genomics.

Mice that lack the gene for integrin β3, or ITGB3 — which regulates the levels of serotonin in the blood — groom themselves frequently and show less interest in stranger mice compared with controls, according to a study published in February in Autism Research as part of a special issue on mouse models in autism.

Six strains of mice lacking a gene associated with fragile X syndrome show radically different behaviors though they share the same mutation, researchers reported in January in Autism Research.

Rare mutations in TSGA14, a component of the centrosome — which is required for the generation of new neurons — may be associated with autism, according to a study published in January in the American Journal of Medical Genetics.

A partial mutation that leads to a milder form of fragile X syndrome causes deficits in learning and memory in mice, and alters the connections between their neurons, according to a study published in January in Neurobiology of Disease.

Two new studies of families carrying glitches on a region of chromosome 16, which has been strongly associated with autism, reveal the wide range of effects caused by the variant and narrow the list of possible culprit genes.

A genome-wide association study has identified risk factors for Asperger syndrome, some of which overlap with chromosomal regions implicated in autism, according to a study in the December issue of Autism Research.

Men with fragile X syndrome have larger brains overall than controls do, but less matter in regions involved in language and social interaction.

The National Institutes of Health is adding a new $1 billion institute for early-stage drug development. But the agency’s plan to fund it by closing the National Center for Research Resources is causing some consternation.